Genentech Forms Special Committee of Independent Directors to Review Roche Proposal Genentech, Inc. (NYSE:DNA) announced today that it has formed a special committee of its Board of Directors, composed of the company's three independent directors, to assess the proposal from Roche to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $89.00 in cash per share. The special committee members are Herbert W. Boyer, Ph.D., Debra L. Reed and Charles A.
Source: http://www.medicalnewstoday.com/sections/pharma_industry/
Pharma Industry / Biotech Industry News From Medical News Today